Urovant began life as an offshoot of Vivek Ramaswamy’s Roivant goliath, but is now firmly a part of the Sumitovant Biopharma family after the life science company bought up the rest of its shares in the biotech.
This comes around a month before Urovant’s PDUFA fate with the FDA for its lead asset vibegron, which it hopes to market as a rival to Astellas’ overactive bladder disorder (OAB) med Myrbetriq.
That FDA decision is set for by Dec. 26, but the company isn’t resting on its laurels, and recently told FierceBiotech it is still pushing hard in R&D, including for its a phase 2a study for URO-902, a gene therapy also for the treatment of OAB.
